Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN. Gonzalez-Angulo AM, et al. J Clin Oncol. 2009 Dec 1;27(34):5700-6. doi: 10.1200/JCO.2009.23.2025. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884543 Free PMC article.
Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.
Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN. Buzdar AU, et al. Among authors: theriault rl. Clin Cancer Res. 2002 May;8(5):1073-9. Clin Cancer Res. 2002. PMID: 12006521 Clinical Trial.
A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH, Booser DJ, Murray JL, Ibrahim NK, Rahman ZU, Valero V, Theriault RL, Rosales MF, Rivera E, Frye D, Ewer M, Ordonez NG, Buzdar AU, Hortobagyi GN. Giordano SH, et al. Among authors: theriault rl. Clin Cancer Res. 2002 Nov;8(11):3360-8. Clin Cancer Res. 2002. PMID: 12429622 Clinical Trial.
The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
Thomas E, Holmes FA, Smith TL, Buzdar AU, Frye DK, Fraschini G, Singletary SE, Theriault RL, McNeese MD, Ames F, Walters R, Hortobagyi GN. Thomas E, et al. Among authors: theriault rl. J Clin Oncol. 2004 Jun 15;22(12):2294-302. doi: 10.1200/JCO.2004.05.207. J Clin Oncol. 2004. PMID: 15197190 Clinical Trial.
Breast cancer treatment guidelines in older women.
Giordano SH, Hortobagyi GN, Kau SW, Theriault RL, Bondy ML. Giordano SH, et al. Among authors: theriault rl. J Clin Oncol. 2005 Feb 1;23(4):783-91. doi: 10.1200/JCO.2005.04.175. J Clin Oncol. 2005. PMID: 15681522
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Buzdar AU, et al. Among authors: theriault rl. J Clin Oncol. 2005 Jun 1;23(16):3676-85. doi: 10.1200/JCO.2005.07.032. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738535 Clinical Trial.
222 results